Simpson Thacher represented the underwriters, led by J.P. Morgan, Jefferies, TD Cowen and Cantor, in connection with the registered follow-on offering of 5,693,070 shares of Class A common stock by Nuvalent, Inc. (“Nuvalent”) and certain selling stockholders. The offering raised approximately $543.4 million in aggregate gross proceeds for Nuvalent and the selling stockholders.
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
The Simpson Thacher team included John O’Connell, Evan Zuckerman, Julie De Keukeleire and Anthony Kuan (Capital Markets); Vanessa Burrows, Alison Peters and Jacob Madden (Healthcare); Paige Brinton (IP); Drew Purcell and Michael Mann (Tax); Pasco Struhs (ECEB); and Andrew Pagliughi (FINRA and Blue Sky).